Mortality rate and gross pathology due to tuberculosis in wild brushtail possums (Trichosurus vulpecula) following low dose subcutaneous injection of Mycobacterium bovis.
Gross pathology due to tuberculosis can be established experimentally in brushtail possums (Trichosurus vulpecula) within 7 weeks of injection of virulent Mycobacterium bovis into subcutaneous connective tissues of the peripheral limbs. This pathology involves lymphadenomegaly and development of gross lesions in peripheral lymph nodes, with subsequent gross lesions in the lungs and reticuloendothelial organs. Using this artificial infection model, we here assessed the mortality rate for possums in the wild, to provide new information on the likely survival period for New Zealand's major wildlife host. Possums were trapped and inoculated with <50 CFU of M. bovis, then fitted with mortality signal emitting radio tracking collars, released and re-tracked for 6 months. Possum survival probability was 89% up to 12 weeks post-injection (p.i.), but cumulative mortality was rapid from then on. The median survival period, based on study of 38 possums, was 18 weeks p.i.; this corresponds with a predicted time interval of 11 weeks between first presentation of TB as palpable lymphadenomegaly and death for an average possum, shorter than period values currently used in possum TB epidemiological modelling. We also examined gross pathology in 11 possums by post mortem necropsy, and confirmed lymphadenomegaly and tuberculous lesions at 7 and 12 weeks p.i. Extra-peripheral gross lesions were more frequent among possums at 12 weeks p.i. than at 7 weeks, while the occurrence of lung lesions (the most likely cause of disease-induced mortality) was apparent in animals at 12 weeks but not at 7 weeks p.i. Our results suggest that the time course of TB from development of gross lesions to mortality may be shorter than previously estimated from field studies of naturally tuberculous possums.
Landcare Research, PO Box 40, Lincoln 7640, New Zealand. nugentg@landcareresearch.co.nz
Graham
G
Nugent
Ivor
I
Yockney
Jackie
J
Whitford
Martin L
ML
Cross
D000818:Animals; D005260:Female; D007279:Injections, Subcutaneous / Q000662:veterinary; D008198:Lymph Nodes / Q000382:microbiology / Q000473:pathology; D008199:Lymphadenitis / Q000382:microbiology / Q000473:pathology; D008297:Male; D009163:Mycobacterium bovis / Q000472:pathogenicity* / Q000502:physiology*; D009520:New Zealand / Q000453:epidemiology; D048330:Trichosurus; D014376:Tuberculosis / Q000382:microbiology / Q000401:mortality / Q000473:pathology / Q000662:veterinary*; D014774:Virulence